Results for "heart failure"
Conditions Encyclopedia Entry 1777007106
** Atrial septal defect (ASD) is a congenital heart defect characterized by an abnormal opening in the atrial septum, the wall of tissue that separates the upper chambers of the heart. **CONTENT:** ### Overview Atrial septal defect (ASD) is a common congenital heart defect that affects approximately 1 in 2,500 births. It occurs when there is an abnormal opening in the atrial septum, the wall of tissue that separates the upper chambers of the heart, known as the left and right atria. This opening allows blood to flow between the two chambers, which can lead to various complications. ASDs can be classified into three main types: ostium secundum, ostium primum, and sinus venosus. ASDs can be present at birth or may not be diagnosed until later in life. In some cases, individuals with ASDs may not experience any symptoms, while others may experience fatigue, shortness of breath, or palpitations. ASDs can also increase the risk of developing other heart problems, such as pulmonary hypertension and heart failure. ### History/Background The first recorded description of ASDs dates back to the 17th century, when the English physician Thomas Sydenham described a case of a patient with a "hole in the heart." However, it wasn't until the 20th century that ASDs were more widely recognized and understood. In the 1950s and 1960s, surgeons began to develop techniques for repairing ASDs, including the use of surgical patches and catheter-based interventions. ### Key Information ASDs can be diagnosed using various tests, including: * Echocardiogram: an ultrasound of the heart that uses sound waves to create images of the heart. * Electrocardiogram (ECG): a test that measures the electrical activity of the heart. * Chest X-ray: a test that uses X-rays to create images of the heart and lungs. * Cardiac catheterization: a test that uses a catheter to inject dye into the heart and take pictures of the heart's blood vessels. Treatment options for ASDs include: * Surgical repair: a surgical procedure that closes the abnormal opening in the atrial septum. * Catheter-based repair: a minimally invasive procedure that uses a catheter to close the abnormal opening. * Watchful waiting: a conservative approach that involves monitoring the individual's condition and treating symptoms as needed. ### Significance ASDs can have significant consequences if left untreated. Complications can include: * Pulmonary hypertension: high blood pressure in the lungs that can lead to heart failure. * Heart failure: a condition in which the heart is unable to pump enough blood to meet the body's needs. * Stroke: a condition in which the blood supply to the brain is interrupted. Early diagnosis and treatment of ASDs can significantly improve outcomes and prevent complications. **INFOBOX:** - Name: Atrial Septal Defect (ASD) - Type: Congenital Heart Defect - Date: First described in the 17th century - Location: Affects the upper chambers of the heart - Known For: Common congenital heart defect that can lead to various complications if left untreated. **TAGS:** congenital heart defect, atrial septal defect, ASD, heart defect, heart disease, pulmonary hypertension, heart failure, stroke, cardiovascular disease.
Health & MedicineCardiomyopathy
** Cardiomyopathy is a heterogeneous group of primary diseases of the heart muscle that impair its ability to pump blood effectively, often progressing from silent stages to heart failure, arrhythmias, and an elevated risk of sudden cardiac death. **CONTENT:** ## Overview **Cardiomyopathy** refers to a collection of disorders in which the myocardium (heart muscle) is structurally and functionally abnormal, without coronary artery disease, hypertension, valvular disease, or congenital heart defects accounting for the changes. The condition can be **genetic**, **acquired**, or **mixed**, and it is traditionally classified into four major phenotypes: **dilated cardiomyopathy (DCM)**, **hypertrophic cardiomyopathy (HCM)**, **arrhythmogenic right ventricular cardiomyopathy (ARVC)**, and **restrictive cardiomyopathy (RCM)**. Early in the disease course many individuals are asymptomatic, and the condition may be discovered incidentally on imaging or during family screening. As myocardial dysfunction worsens, patients commonly develop **shortness of breath**, **fatigue**, and **peripheral edema** due to the onset of **heart failure**. Electrical instability of the diseased tissue can produce **irregular heartbeats (arrhythmias)**, syncope, or even **sudden cardiac death (SCD)**, especially in HCM and ARVC. Prompt evaluation by a cardiologist is essential whenever new dyspnea, unexplained fainting, palpitations, or swelling of the legs appear. ## History/Background The term “cardiomyopathy” entered the medical lexicon in the early 20th century, but systematic description of distinct subtypes began in the 1950s. In 1958, Dr. Donald Teare published the first pathological series of **hypertrophic cardiomyopathy**, recognizing it as a primary myocardial disease rather than a consequence of hypertension. The 1970s saw the emergence of **dilated cardiomyopathy** as a separate entity, largely through the work of Dr. William Braunwald and colleagues, who linked viral infections and toxins to ventricular dilation. The 1990s brought molecular genetics to the forefront: the discovery of mutations in the **β‑myosin heavy‑chain** gene (MYH7) and **myosin‑binding protein C** (MYBPC3) clarified the hereditary nature of HCM. In 1994, the **Task Force of the European Society of Cardiology** formalized diagnostic criteria for **arrhythmogenic right ventricular cardiomyopathy**, emphasizing fibro‑fatty replacement of the right ventricular wall. Since then, advances in cardiac MRI, genetic sequencing, and device therapy (e.g., implantable cardioverter‑defibrillators) have transformed both diagnosis and management. ## Key Information - **Epidemiology:** Cardiomyopathy affects roughly 1 in 500 adults worldwide; HCM is the most common inherited cardiac disorder, while DCM accounts for about 50 % of non‑ischemic heart failure cases. - **Pathophysiology:** In DCM, ventricular walls thin and chambers enlarge, reducing **ejection fraction** (< 40 %). HCM features asymmetric septal hypertrophy, often with preserved or hyperdynamic systolic function but impaired diastolic filling. ARVC involves replacement of right‑ventricular myocardium with adipose and fibrous tissue, predisposing to ventricular tachycardia. RCM is characterized by stiff ventricles that cannot relax, leading to restrictive filling patterns. - **Genetics:** Over 60 genes have been implicated, most commonly those encoding sarcomeric proteins (e.g., MYH7, MYBPC3), desmosomal proteins (PKP2, DSP) for ARVC, and cytoskeletal proteins (LMNA) for DCM. Genetic testing is recommended for patients with a family history or early‑onset disease. - **Diagnosis:** A combination of **echocardiography**, **cardiac magnetic resonance imaging (CMR)**, **electrocardiography (ECG)**, and, when indicated, **endomyocardial biopsy** establishes the phenotype. Biomarkers such as **NT‑proBNP** aid in assessing heart‑failure severity. - **Management:** Treatment is phenotype‑specific. For DCM and heart‑failure symptoms, guideline‑directed medical therapy includes **ACE inhibitors**, **beta‑blockers**, **ARNI**, and **mineralocorticoid receptor antagonists**. HCM management focuses on **β‑blockers**, **non‑dihydropyridine calcium‑channel blockers**, and **disopyramide** to relieve outflow obstruction; septal reduction (surgical myectomy or alcohol septal ablation) is considered for refractory cases. ARVC patients benefit from **anti‑arrhythmic drugs**, lifestyle restriction (avoidance of intense endurance exercise), and **implantable cardioverter‑defibrillators (ICDs)** for SCD prevention. Heart transplantation remains an option for end‑stage disease unresponsive to medical therapy. - **Prognosis & Follow‑up:** Regular follow‑up with imaging and rhythm monitoring is crucial. Patients with HCM have a lifetime SCD risk of 1 %–2 % without intervention; ICD implantation reduces mortality dramatically. ## Significance Cardiomyopathy represents a leading cause of **non‑ischemic heart failure**, **sudden cardiac death in young athletes**, and **transplant‑eligible heart disease**. Understanding its genetic underpinnings has propelled precision medicine, allowing at‑risk relatives to undergo cascade screening and early intervention. Public‑health initiatives that promote **pre‑participation cardiac screening** in sports, and the widespread availability of ICDs, have saved countless lives. Moreover, research into myocardial remodeling, gene therapy, and novel pharmacologic agents (e.g., myosin inhibitors like mavacamten for HCM) continues to reshape therapeutic horizons. For patients, early recognition and multidisciplinary care can transform a potentially fatal condition into a manageable chronic disease, preserving quality of life and functional capacity. **INFOBOX:** - Name: Cardiomyopathy - Type: Primary myocardial disease (cardiac muscle disorder) - Date: First formal classification – 1958 (HCM) / 1970s (DCM) - Location: Global (affects individuals worldwide) - Known For: Impaired cardiac pumping function, risk of heart failure and sudden cardiac death **TAGS:** cardiomyopathy, heart failure, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, genetics, sudden cardiac death, cardiac imaging *If you experience unexplained shortness of breath, fainting, palpitations, or swelling of the legs, seek evaluation by a qualified healthcare professional promptly.*
Health & MedicineConditions Encyclopedia Entry 1777821485
** Hypertrophic cardiomyopathy (HCM) is a genetic disorder that affects the heart muscle, causing it to thicken and potentially lead to heart failure, arrhythmias, and sudden cardiac death. **CONTENT:** ### Overview Hypertrophic cardiomyopathy (HCM) is a complex and often misunderstood condition that affects the heart muscle. It is characterized by the thickening of the heart muscle, which can lead to a range of symptoms and complications. HCM is a leading cause of sudden cardiac death in young athletes, and it is estimated to affect approximately 1 in 500 people worldwide. Despite its prevalence, HCM remains a relatively unknown condition, and many people are unaware of the risks and symptoms associated with it. HCM is a genetic disorder, meaning that it is inherited from one's parents. The condition is caused by mutations in genes that code for proteins involved in the structure and function of the heart muscle. These mutations can lead to the abnormal growth and thickening of the heart muscle, which can disrupt the normal functioning of the heart. ### History/Background The first descriptions of HCM date back to the 19th century, when physicians began to notice a pattern of heart muscle thickening in patients with sudden cardiac death. However, it wasn't until the 1960s that the condition was formally described and named hypertrophic cardiomyopathy. Since then, significant advances have been made in our understanding of the condition, including the identification of the genetic mutations responsible for HCM. In the 1980s, the development of echocardiography and other imaging techniques allowed for the non-invasive diagnosis of HCM. This led to a significant increase in the detection of the condition, and it is now estimated that HCM affects approximately 1 in 500 people worldwide. ### Key Information HCM is a complex condition that can manifest in a range of ways. The symptoms of HCM can include: * Chest pain or discomfort * Shortness of breath * Fatigue * Dizziness or lightheadedness * Palpitations or irregular heartbeat In some cases, HCM can lead to more severe complications, including: * Heart failure * Arrhythmias * Sudden cardiac death The diagnosis of HCM typically involves a combination of clinical evaluation, imaging studies, and genetic testing. Echocardiography is often used to visualize the heart muscle and assess its thickness and function. Genetic testing can also be used to identify the specific genetic mutations responsible for HCM. ### Significance HCM is a significant public health concern, particularly in young athletes. Sudden cardiac death is a leading cause of death in this population, and HCM is a major contributor to this risk. In addition, HCM can have a significant impact on an individual's quality of life, leading to symptoms and complications that can affect daily activities and overall well-being. **INFOBOX:** - **Name:** Hypertrophic Cardiomyopathy - **Type:** Genetic disorder - **Date:** 1960s (first formal description) - **Location:** Worldwide - **Known For:** Leading cause of sudden cardiac death in young athletes **TAGS:** Hypertrophic cardiomyopathy, genetic disorder, heart muscle thickening, sudden cardiac death, arrhythmias, heart failure, echocardiography, genetic testing, public health concern.
Health & MedicineConditions Encyclopedia Entry 1775640364
Atrial Septal Defect (ASD) is a congenital heart defect characterized by an abnormal opening in the wall between the heart's two upper chambers, leading to abnormal blood flow and potential complications.
Health & MedicineConditions Encyclopedia Entry 1777013884
** Hypertrophic cardiomyopathy (HCM) is a genetic disorder that affects the heart muscle, causing it to thicken and become stiff, leading to potential complications such as heart failure, arrhythmias, and sudden cardiac death. **CONTENT:** ## Overview Hypertrophic cardiomyopathy (HCM) is a complex and often misunderstood heart condition that affects millions of people worldwide. It is characterized by the thickening of the heart muscle, which can lead to a range of symptoms and complications. HCM is a leading cause of sudden cardiac death in young athletes and is often associated with other medical conditions, such as arrhythmias and heart failure. Despite its prevalence, HCM remains a relatively unknown condition, and many people are unaware of the risks and warning signs associated with it. HCM is a genetic disorder that affects the heart muscle, causing it to thicken and become stiff. This can lead to a range of symptoms, including chest pain, shortness of breath, and fatigue. In some cases, HCM can also cause arrhythmias, which are abnormal heart rhythms that can be life-threatening. If left untreated, HCM can lead to serious complications, including heart failure, stroke, and sudden cardiac death. ## History/Background HCM has been described in medical literature for over a century, but it was not until the 1960s that the condition was fully understood and recognized as a distinct medical entity. In the 1970s and 1980s, researchers began to identify the genetic causes of HCM, and in the 1990s, the first genetic tests for the condition were developed. Today, HCM is recognized as a leading cause of sudden cardiac death in young athletes, and efforts are underway to improve diagnosis and treatment of the condition. ## Key Information HCM is a genetic disorder that affects the heart muscle, causing it to thicken and become stiff. The condition is caused by mutations in genes that code for proteins involved in the structure and function of the heart muscle. HCM can be inherited in an autosomal dominant pattern, meaning that a single copy of the mutated gene is enough to cause the condition. In some cases, HCM can also be caused by other factors, such as high blood pressure or obesity. Symptoms of HCM can vary widely, but common symptoms include: * Chest pain or discomfort * Shortness of breath * Fatigue or weakness * Dizziness or lightheadedness * Palpitations or irregular heartbeats In some cases, HCM can also cause more serious complications, including: * Arrhythmias, which are abnormal heart rhythms that can be life-threatening * Heart failure, which occurs when the heart is unable to pump enough blood to meet the body's needs * Stroke, which occurs when the blood supply to the brain is interrupted ## Significance HCM is a significant public health concern, particularly in young athletes. According to the American Heart Association, HCM is the leading cause of sudden cardiac death in young athletes, accounting for up to 40% of all sudden cardiac deaths in this population. In addition, HCM is a leading cause of heart failure and stroke in adults, and is associated with a range of other medical conditions, including high blood pressure and obesity. ## INFOBOX: - **Name:** Hypertrophic Cardiomyopathy (HCM) - **Type:** Genetic disorder - **Date:** First described in medical literature in the 19th century - **Location:** Affects people worldwide - **Known For:** Leading cause of sudden cardiac death in young athletes ## TAGS: Hypertrophic cardiomyopathy, heart muscle disease, genetic disorder, arrhythmias, heart failure, stroke, sudden cardiac death, young athletes, heart health.
Health & MedicineConditions Encyclopedia Entry 1780319348
** This encyclopedia entry is about **Mitochondrial Myopathies**, a group of rare genetic disorders affecting the mitochondria, the energy-producing structures within cells. **CONTENT** ### Overview Mitochondrial Myopathies (MM) are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. These disorders are caused by mutations in the mitochondrial DNA, which is inherited from one's mother. Mitochondrial myopathies can affect various parts of the body, including the muscles, nervous system, and other organs. The symptoms and severity of MM vary widely among individuals, making diagnosis and treatment challenging. Mitochondrial myopathies are characterized by a range of symptoms, including muscle weakness, fatigue, exercise intolerance, and muscle pain. Some individuals may also experience neurological symptoms, such as seizures, vision loss, and hearing loss. In severe cases, MM can lead to life-threatening complications, such as heart failure, respiratory failure, and kidney failure. ### History/Background The first reported case of mitochondrial myopathy was in 1962, when a British neurologist, Dr. Keith Morgan, described a patient with a rare muscle disorder. However, it wasn't until the 1980s that the genetic basis of MM was discovered. Researchers identified mutations in the mitochondrial DNA as the cause of these disorders. Since then, numerous studies have been conducted to understand the genetic and molecular mechanisms underlying MM. ### Key Information Mitochondrial myopathies are caused by mutations in the mitochondrial DNA, which is inherited from one's mother. These mutations affect the production of energy within cells, leading to a range of symptoms and complications. There are several types of MM, including: * **Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS)**: A severe form of MM characterized by muscle weakness, seizures, and stroke-like episodes. * **Myoclonic Epilepsy with Ragged-Red Fibers (MERRF)**: A type of MM characterized by muscle weakness, seizures, and vision loss. * **Kearns-Sayre Syndrome (KSS)**: A rare form of MM characterized by muscle weakness, vision loss, and heart problems. ### Significance Mitochondrial myopathies are rare disorders, affecting approximately 1 in 5,000 people worldwide. However, they can have a significant impact on individuals and families affected by these disorders. Early diagnosis and treatment can improve the quality of life for individuals with MM, but there is currently no cure for these disorders. Research into mitochondrial myopathies has led to a greater understanding of the genetic and molecular mechanisms underlying these disorders. This knowledge has also led to the development of new treatments and therapies, such as gene therapy and mitochondrial-targeted antioxidants. **INFOBOX** - **Name:** Mitochondrial Myopathies - **Type:** Genetic disorder - **Date:** 1962 (first reported case) - **Location:** Worldwide - **Known For:** Rare genetic disorders affecting the mitochondria **TAGS:** Mitochondrial myopathies, genetic disorders, mitochondrial DNA, muscle weakness, fatigue, exercise intolerance, muscle pain, neurological symptoms, seizures, vision loss, hearing loss, heart failure, respiratory failure, kidney failure, MELAS, MERRF, KSS, gene therapy, mitochondrial-targeted antioxidants.
Health & MedicineConditions Encyclopedia Entry 1777118285
** Hypertrophic Cardiomyopathy (HCM) is a genetic heart condition characterized by abnormal thickening of the heart muscle, leading to impaired heart function and increased risk of sudden cardiac death. **CONTENT:** ### Overview Hypertrophic Cardiomyopathy (HCM) is a complex and potentially life-threatening heart condition that affects approximately 1 in 500 people worldwide. It is the most common cause of sudden cardiac death in young athletes and is often associated with **arrhythmias**, **heart failure**, and **sudden cardiac arrest**. HCM is a genetic disorder that affects the heart muscle, causing it to become abnormally thickened, which can lead to impaired heart function and increased risk of complications. HCM can affect people of all ages, but it is most commonly diagnosed in young adults and children. The condition can be inherited in an **autosomal dominant** pattern, meaning that a single copy of the mutated gene is enough to cause the condition. However, in some cases, HCM can occur spontaneously without a family history of the condition. ### History/Background The first descriptions of HCM date back to the 19th century, but it was not until the 1970s that the condition was fully characterized and recognized as a distinct clinical entity. In the 1980s, the discovery of the **MYBPC3** gene, which is one of the most common genes associated with HCM, marked a significant breakthrough in understanding the genetic basis of the condition. ### Key Information HCM is characterized by the following key features: * **Left ventricular hypertrophy**: Abnormal thickening of the left ventricle, which can lead to impaired heart function and increased risk of complications. * **Symptoms**: Shortness of breath, chest pain, fainting, and palpitations are common symptoms of HCM. * **Genetic basis**: HCM is caused by mutations in genes that code for proteins involved in heart muscle contraction and relaxation. * **Risk factors**: Family history, age, and certain genetic mutations increase the risk of developing HCM. * **Complications**: HCM can lead to **arrhythmias**, **heart failure**, and **sudden cardiac arrest**. ### Significance HCM is a significant public health concern due to its high prevalence and potential for serious complications. Early diagnosis and treatment can significantly improve outcomes for individuals with HCM. However, many cases of HCM remain undiagnosed, and the condition is often misdiagnosed as other heart conditions. **INFOBOX:** - Name: Hypertrophic Cardiomyopathy (HCM) - Type: Genetic heart condition - Date: 1970s (first descriptions), 1980s (discovery of MYBPC3 gene) - Location: Worldwide - Known For: Most common cause of sudden cardiac death in young athletes **TAGS:** Hypertrophic Cardiomyopathy, HCM, genetic heart condition, arrhythmias, heart failure, sudden cardiac arrest, autosomal dominant, MYBPC3 gene, left ventricular hypertrophy, cardiac complications.
Health & MedicineConditions Encyclopedia Entry 1778333057
Hypertrophic cardiomyopathy (HCM) is a genetic heart condition characterized by thickening of the heart muscle, which can lead to heart failure, arrhythmias, and sudden cardiac death.
Health & MedicineConditions Encyclopedia Entry 1780066043
Pneumonia is a serious and potentially life-threatening infection that inflames the air sacs in the lungs, causing cough, fever, and difficulty breathing.
Health & MedicineConditions Encyclopedia Entry 1776670151
** Mitral Valve Prolapse (MVP) is a heart condition characterized by the abnormal movement of the mitral valve, which separates the left atrium and left ventricle of the heart, leading to potential complications and symptoms. **CONTENT:** ## Overview Mitral Valve Prolapse (MVP) is a relatively common heart condition affecting approximately 2-3% of the general population. It is characterized by the abnormal movement of the mitral valve, which separates the left atrium and left ventricle of the heart. In a normal heart, the mitral valve moves in a coordinated manner, allowing blood to flow from the left atrium to the left ventricle during contraction. In MVP, the valve leaflets bulge or prolapse into the left atrium during contraction, potentially causing problems with blood flow and cardiac function. MVP can be asymptomatic, but symptoms may include chest pain, shortness of breath, fatigue, and palpitations. In some cases, MVP can lead to complications such as mitral regurgitation (leakage of blood back into the left atrium), arrhythmias (abnormal heart rhythms), and even heart failure. ## History/Background The first reported case of MVP dates back to 1769, when the French physician Jean-Baptiste Leblanc described a patient with a "bulging" mitral valve. However, it wasn't until the 1960s that MVP began to gain recognition as a distinct medical condition. The development of echocardiography (ultrasound imaging of the heart) in the 1970s revolutionized the diagnosis and management of MVP, allowing for more accurate assessment of the mitral valve and its function. ## Key Information MVP can be classified into two main types: Barlow's syndrome and fibroelastic deficiency. Barlow's syndrome is characterized by a more severe prolapse of the mitral valve leaflets, often associated with mitral regurgitation. Fibroelastic deficiency, on the other hand, is characterized by a milder prolapse and less severe symptoms. Key findings in MVP include: * **Mitral valve prolapse**: The mitral valve leaflets bulge or prolapse into the left atrium during contraction. * **Mitral regurgitation**: Leaking of blood back into the left atrium due to the prolapse of the mitral valve. * **Arrhythmias**: Abnormal heart rhythms, such as atrial fibrillation or ventricular tachycardia. * **Heart failure**: In severe cases, MVP can lead to heart failure, characterized by symptoms such as shortness of breath, fatigue, and swelling. ## Significance MVP is a significant condition due to its potential complications and impact on quality of life. While many people with MVP are asymptomatic, others may experience debilitating symptoms and complications. The significance of MVP lies in its potential to affect cardiac function and overall health. **INFOBOX:** - **Name:** Mitral Valve Prolapse (MVP) - **Type:** Heart condition - **Date:** First reported case in 1769 - **Location:** Affects approximately 2-3% of the general population - **Known For:** Characterized by abnormal movement of the mitral valve, leading to potential complications and symptoms **TAGS:** Heart conditions, mitral valve, prolapse, mitral regurgitation, arrhythmias, heart failure, echocardiography, Barlow's syndrome, fibroelastic deficiency.
Health & MedicineConditions Encyclopedia Entry 1779121806
** Hypertrophic cardiomyopathy (HCM) is a genetic heart condition characterized by the thickening of the heart muscle, which can lead to abnormal heart function and potentially life-threatening complications. **CONTENT:** ### Overview Hypertrophic cardiomyopathy (HCM) is a complex heart condition that affects the heart muscle, causing it to become thickened and abnormal. This thickening, known as hypertrophy, can lead to a range of symptoms, from mild to severe, and can increase the risk of sudden cardiac death. HCM is a leading cause of sudden cardiac death in young athletes and is often inherited in an autosomal dominant pattern, meaning that a single copy of the mutated gene is enough to cause the condition. HCM can affect people of all ages, but it is most commonly diagnosed in young adults and children. The condition is often asymptomatic, but when symptoms do occur, they can include chest pain, shortness of breath, fatigue, and palpitations. In some cases, HCM can lead to more severe complications, such as heart failure, arrhythmias, and sudden cardiac death. ### History/Background HCM has been recognized as a distinct heart condition for over a century, but it was not until the 1960s that the condition was fully described and its genetic basis was identified. Since then, significant advances have been made in understanding the underlying causes of HCM and developing effective treatments. In 1990, the first genetic mutations associated with HCM were identified, and since then, numerous other mutations have been linked to the condition. ### Key Information HCM is a genetic disorder that affects the heart muscle, causing it to become thickened and abnormal. The condition is caused by mutations in genes that code for proteins involved in the structure and function of the heart muscle. These mutations can lead to a range of symptoms, from mild to severe, and can increase the risk of sudden cardiac death. There are several types of HCM, including: * **Obstructive HCM**: characterized by a narrowing of the left ventricular outflow tract, which can lead to symptoms such as chest pain and shortness of breath. * **Non-obstructive HCM**: characterized by thickening of the heart muscle without a significant narrowing of the left ventricular outflow tract. * **Familial HCM**: inherited in an autosomal dominant pattern, meaning that a single copy of the mutated gene is enough to cause the condition. * **Sporadic HCM**: not inherited and occurs in individuals without a family history of the condition. ### Significance HCM is a significant health concern, particularly in young athletes and individuals with a family history of the condition. Early diagnosis and treatment can significantly improve outcomes and reduce the risk of sudden cardiac death. In addition, advances in genetic testing and imaging technologies have improved our ability to diagnose and manage HCM. **INFOBOX:** - **Name:** Hypertrophic Cardiomyopathy (HCM) - **Type:** Genetic heart condition - **Date:** 1960s (first described) - **Location:** Worldwide - **Known For:** Leading cause of sudden cardiac death in young athletes **TAGS:** Hypertrophic cardiomyopathy, genetic heart condition, sudden cardiac death, heart muscle thickening, genetic mutations, obstructive HCM, non-obstructive HCM, familial HCM, sporadic HCM, heart failure, arrhythmias.
Health & MedicineConditions Encyclopedia Entry 1779068467
** Hypertrophic cardiomyopathy (HCM) is a genetic heart condition characterized by the thickening of the heart muscle, which can lead to abnormal heart function and potentially life-threatening complications. **CONTENT:** ### Overview Hypertrophic cardiomyopathy (HCM) is a complex and potentially life-threatening heart condition that affects approximately 1 in 500 people worldwide. It is the most common cause of sudden cardiac death in young athletes and is often inherited in an autosomal dominant pattern. HCM is characterized by the thickening of the heart muscle, which can lead to abnormal heart function, including reduced cardiac output, arrhythmias, and increased risk of heart failure. The symptoms of HCM can vary widely, ranging from asymptomatic to severe shortness of breath, chest pain, and fainting spells. In some cases, HCM may not cause any noticeable symptoms until it has progressed to a more advanced stage. The condition can be diagnosed through a combination of physical examination, electrocardiogram (ECG), echocardiogram, and cardiac magnetic resonance imaging (MRI). ### History/Background The first reported case of HCM dates back to 1900, when a British physician named James Parkinson described a patient with a thickened heart muscle. However, it wasn't until the 1960s that the condition was formally recognized as a distinct clinical entity. Since then, significant advances have been made in understanding the genetic and molecular mechanisms underlying HCM, as well as the development of effective treatments and management strategies. ### Key Information HCM is caused by mutations in genes that code for proteins involved in the regulation of cardiac muscle contraction and relaxation. The most common genes associated with HCM are MYBPC3, MYH7, and TNNT2. The condition can be inherited in an autosomal dominant pattern, meaning that a single copy of the mutated gene is sufficient to cause the condition. The diagnosis of HCM typically involves a combination of clinical evaluation, ECG, echocardiogram, and cardiac MRI. The American Heart Association recommends that individuals with a family history of HCM undergo regular screening, including ECG and echocardiogram, starting at age 12. ### Significance HCM is a significant public health concern due to its high prevalence and potential for life-threatening complications. According to the American Heart Association, HCM is responsible for approximately 25% of sudden cardiac deaths in young athletes. Early detection and management of HCM can significantly improve outcomes and reduce the risk of complications. ### INFOBOX: - **Name:** Hypertrophic Cardiomyopathy (HCM) - **Type:** Genetic heart condition - **Date:** 1900 (first reported case) - **Location:** Worldwide - **Known For:** Most common cause of sudden cardiac death in young athletes ### TAGS: Genetic heart conditions, hypertrophic cardiomyopathy, sudden cardiac death, cardiac muscle thickening, heart failure, arrhythmias, cardiac MRI, echocardiogram, electrocardiogram, genetic testing. **Important Note:** If you or a family member has been diagnosed with HCM, it is essential to seek regular medical care and follow-up appointments with a cardiologist. Early detection and management of HCM can significantly improve outcomes and reduce the risk of complications.
Health & MedicineConditions Encyclopedia Entry 1779250819
Mitral Valve Prolapse (MVP) is a heart condition characterized by the mitral valve leaflets bulging back into the left atrium during heart contractions, which can lead to symptoms such as chest pain, shortness of breath, and palpitations.
Health & MedicineConditions Encyclopedia Entry 1780867227
Hypertrophic cardiomyopathy (HCM) is a genetic disorder that affects the heart muscle, leading to thickening of the heart walls and potentially life-threatening complications.
Health & MedicineConditions Encyclopedia Entry 1780212247
Mitral valve prolapse (MVP) is a condition where the mitral valve, which separates the left atrium and left ventricle of the heart, does not close properly, leading to potential complications. ## Overview Mitral valve prolapse (MVP) is a relatively common heart condition characterized by the abnormal movement of the mitral valve, which separates the left atrium and left ventricle of the heart. In a normal heart, the mitral valve closes tightly to prevent blood from flowing backward into the left atrium. However, in individuals with MVP, the valve leaflets bulge (prolapse) into the left atrium when the heart contracts, potentially leading to complications such as mitral regurgitation (leaking of blood backward into the left atrium) and arrhythmias. MVP can be asymptomatic, and many people with the condition do not experience any noticeable symptoms. However, some individuals may experience symptoms such as chest pain, shortness of breath, palpitations, or fatigue. In severe cases, MVP can lead to complications such as heart failure, endocarditis (infection of the heart valve), or even sudden cardiac death. ## History/Background The first reported cases of mitral valve prolapse date back to the 19th century, but it wasn't until the 1960s that the condition was formally described and recognized as a distinct clinical entity. Since then, numerous studies have been conducted to better understand the causes, symptoms, and treatment options for MVP. In 1976, the American Heart Association (AHA) published its first guidelines for the diagnosis and management of MVP, which have been updated several times since then. ## Key Information Key facts about mitral valve prolapse include: * **Prevalence**: MVP affects approximately 2-3% of the general population, with a higher incidence in women and individuals with a family history of the condition. * **Causes**: The exact cause of MVP is still unknown, but it is believed to be related to abnormalities in the mitral valve leaflets, chordae tendineae, or papillary muscles. * **Symptoms**: Symptoms of MVP can vary widely, ranging from asymptomatic to severe chest pain, shortness of breath, or palpitations. * **Complications**: Untreated MVP can lead to complications such as mitral regurgitation, arrhythmias, heart failure, endocarditis, or sudden cardiac death. * **Diagnosis**: MVP is typically diagnosed using echocardiography (ultrasound imaging of the heart) or cardiac MRI. * **Treatment**: Treatment options for MVP depend on the severity of the condition and may include lifestyle modifications, medications, or surgical repair of the mitral valve. ## Significance Mitral valve prolapse is a significant condition that requires prompt medical attention to prevent complications. Understanding the causes, symptoms, and treatment options for MVP is essential for individuals with the condition and their healthcare providers. By recognizing the importance of early diagnosis and treatment, individuals with MVP can reduce their risk of complications and improve their overall quality of life. INFOBOX: - Name: Mitral Valve Prolapse - Type: Heart condition - Date: 1960s (first reported cases) - Location: Global - Known For: Abnormal movement of the mitral valve, potential complications TAGS: Mitral valve prolapse, heart condition, mitral regurgitation, arrhythmias, heart failure, endocarditis, sudden cardiac death, echocardiography, cardiac MRI.
Health & MedicineConditions Encyclopedia Entry 1779303244
Mitral Valve Prolapse (MVP) is a heart condition characterized by the mitral valve leaflets bulging back into the left atrium during heart contractions, potentially leading to complications such as mitral regurgitation and arrhythmias.
Health & MedicineConditions Encyclopedia Entry 1780344929
** **Hypertrophic Cardiomyopathy (HCM)** is a genetic heart condition characterized by thickening of the heart muscle, leading to potential complications such as heart failure, arrhythmias, and sudden cardiac death. **CONTENT:** ## Overview Hypertrophic Cardiomyopathy (HCM) is a complex genetic disorder affecting the heart muscle, causing it to thicken and become stiff. This condition can lead to various complications, including heart failure, arrhythmias, and sudden cardiac death. HCM is the most common cause of sudden cardiac death in young athletes and is often associated with a family history of the condition. The exact prevalence of HCM is difficult to determine, but it is estimated to affect approximately 1 in 500 people worldwide. HCM can be caused by mutations in various genes that code for proteins essential for heart muscle function. These mutations can lead to the production of abnormal proteins that accumulate in the heart muscle, causing it to thicken and become stiff. The thickened heart muscle can obstruct blood flow, leading to symptoms such as chest pain, shortness of breath, and fatigue. ## History/Background The first reported cases of HCM date back to the 19th century, but it was not until the 1960s that the condition was described as a distinct clinical entity. In the 1970s and 1980s, researchers began to identify the genetic causes of HCM, and since then, numerous studies have shed light on the molecular mechanisms underlying the condition. Today, HCM is recognized as a leading cause of sudden cardiac death in young athletes, and efforts are being made to improve diagnosis, treatment, and prevention of the condition. ## Key Information Key facts about HCM include: * **Genetic basis**: HCM is caused by mutations in genes that code for proteins essential for heart muscle function, such as myosin heavy chain (MYH7) and troponin T (TNNT2). * **Symptoms**: Common symptoms of HCM include chest pain, shortness of breath, fatigue, and palpitations. * **Complications**: Untreated HCM can lead to complications such as heart failure, arrhythmias, and sudden cardiac death. * **Diagnosis**: Diagnosis of HCM typically involves a combination of clinical evaluation, electrocardiogram (ECG), echocardiogram, and genetic testing. * **Treatment**: Treatment options for HCM include medications to reduce symptoms, implantable cardioverter-defibrillators (ICDs) to prevent sudden cardiac death, and surgical procedures to relieve obstruction of blood flow. ## Significance HCM is a significant public health concern due to its potential to cause sudden cardiac death in young athletes and its impact on quality of life. Efforts to improve diagnosis, treatment, and prevention of HCM are ongoing, and researchers continue to explore new therapeutic strategies to address the condition. Understanding the genetic and molecular mechanisms underlying HCM is crucial for developing effective treatments and improving patient outcomes. **INFOBOX:** - Name: Hypertrophic Cardiomyopathy - Type: Genetic heart condition - Date: First reported cases in the 19th century - Location: Worldwide - Known For: Most common cause of sudden cardiac death in young athletes **TAGS:** Hypertrophic Cardiomyopathy, genetic heart condition, sudden cardiac death, heart failure, arrhythmias, cardiac arrest, genetic testing, implantable cardioverter-defibrillator, surgical procedures, heart muscle disease.
Health & MedicineConditions Encyclopedia Entry 1779165139
** Hypertrophic cardiomyopathy (HCM) is a genetic disorder that affects the heart muscle, causing it to thicken and become stiff, leading to potential heart failure and sudden cardiac death. **CONTENT:** ### Overview Hypertrophic cardiomyopathy (HCM) is a complex and potentially life-threatening heart condition that affects approximately 1 in 500 people worldwide. It is the most common cause of sudden cardiac death in young athletes and is often inherited in an autosomal dominant pattern. HCM is characterized by the thickening of the heart muscle, particularly in the left ventricle, which can lead to impaired heart function and increased risk of complications. In individuals with HCM, the heart muscle becomes abnormally thick, which can obstruct blood flow and lead to symptoms such as chest pain, shortness of breath, and fatigue. In severe cases, HCM can cause life-threatening arrhythmias, heart failure, and even sudden cardiac death. Early diagnosis and treatment are crucial in managing HCM and preventing complications. ### History/Background The first reported cases of HCM date back to the 19th century, but it wasn't until the 1960s that the condition was formally described and named. Since then, significant advances have been made in understanding the genetic and molecular mechanisms underlying HCM. In 1990, the first genetic mutation associated with HCM was identified, and since then, numerous other mutations have been linked to the condition. ### Key Information HCM is a genetic disorder caused by mutations in genes that code for proteins involved in heart muscle contraction and relaxation. The most common mutations affect the genes encoding for cardiac myosin heavy chain (MYH7), cardiac troponin T (TNNT2), and cardiac myosin binding protein C (MYBPC3). These mutations can lead to abnormal heart muscle function, thickening, and stiffness. Symptoms of HCM can vary widely and may include: * Chest pain or angina * Shortness of breath or fatigue * Dizziness or lightheadedness * Palpitations or irregular heartbeat * Syncope (fainting) In addition to genetic testing, diagnosis of HCM typically involves a combination of: * Echocardiogram (ultrasound of the heart) * Cardiac MRI (magnetic resonance imaging) * Electrocardiogram (ECG) * Exercise stress test ### Significance HCM is a significant public health concern, particularly among young athletes and individuals with a family history of the condition. Early diagnosis and treatment can significantly improve outcomes and prevent complications. In fact, studies have shown that individuals with HCM who receive timely and appropriate treatment have a significantly reduced risk of sudden cardiac death. **INFOBOX:** - **Name:** Hypertrophic Cardiomyopathy (HCM) - **Type:** Genetic disorder - **Date:** First reported cases in the 19th century, formally described in the 1960s - **Location:** Worldwide, with a higher prevalence in certain populations - **Known For:** Most common cause of sudden cardiac death in young athletes **TAGS:** Hypertrophic cardiomyopathy, genetic disorder, heart muscle thickening, sudden cardiac death, young athletes, inherited condition, cardiac arrhythmias, heart failure, genetic testing, echocardiogram, cardiac MRI, electrocardiogram, exercise stress test.
Health & MedicineConditions Encyclopedia Entry 1780143381
** Hypertrophic cardiomyopathy (HCM) is a genetic disorder that affects the heart muscle, causing it to become thickened and potentially life-threatening. **CONTENT:** ## Overview Hypertrophic cardiomyopathy (HCM) is a condition in which the heart muscle becomes abnormally thick, leading to a range of symptoms and complications. It is the most common cause of sudden cardiac death in young athletes and is often inherited. HCM can affect people of any age, but it is most commonly diagnosed in young adults. The condition can be caused by mutations in genes that code for proteins in the heart muscle, leading to abnormal heart function and potentially life-threatening complications. HCM can be classified into several subtypes, including: * **Asymmetric septal hypertrophy**: This is the most common subtype, characterized by thickening of the heart muscle on one side of the heart. * **Symmetric septal hypertrophy**: This subtype is characterized by thickening of the heart muscle on both sides of the heart. * **Apical hypertrophic cardiomyopathy**: This subtype is characterized by thickening of the heart muscle at the apex (tip) of the heart. ## History/Background HCM has been recognized for centuries, with descriptions of the condition dating back to the 17th century. However, it was not until the 1960s that the condition was formally described and named. In the 1970s and 1980s, researchers began to identify the genetic causes of HCM, and in the 1990s, the first genetic tests for the condition were developed. ## Key Information * **Prevalence**: HCM affects approximately 1 in 500 people in the general population. * **Genetics**: HCM is caused by mutations in genes that code for proteins in the heart muscle, including the **MYBPC3**, **MYH7**, and **TNNI3** genes. * **Symptoms**: Symptoms of HCM can include chest pain, shortness of breath, fatigue, and palpitations. * **Complications**: Complications of HCM can include **sudden cardiac death**, heart failure, and arrhythmias. * **Diagnosis**: Diagnosis of HCM is typically made using **echocardiography**, **cardiac magnetic resonance imaging (MRI)**, and **electrocardiography (ECG)**. * **Treatment**: Treatment of HCM typically involves **beta blockers**, **anti-arrhythmics**, and **surgery** to relieve symptoms and prevent complications. ## Significance HCM is a significant condition that can have a major impact on an individual's quality of life and life expectancy. It is essential for individuals with HCM to work closely with their healthcare provider to manage symptoms and prevent complications. Regular monitoring and follow-up care are crucial to ensure that the condition does not progress and to prevent sudden cardiac death. **INFOBOX:** - Name: Hypertrophic Cardiomyopathy - Type: Genetic disorder - Date: 1960s (first formal description) - Location: Global - Known For: Most common cause of sudden cardiac death in young athletes **TAGS:** Hypertrophic cardiomyopathy, genetic disorder, heart muscle, cardiomyopathy, sudden cardiac death, arrhythmias, heart failure, echocardiography, cardiac MRI, electrocardiography, beta blockers, anti-arrhythmics, surgery.
Health & MedicineConditions Encyclopedia Entry 1778951841
Hypertrophic cardiomyopathy (HCM) is a genetic heart condition characterized by the thickening of the heart muscle, which can lead to heart failure, arrhythmias, and sudden cardiac death.